Adjuvant dabrafenib-trametinib provides ‘real chance to cure’ BRAF-mutant melanoma

Source: Healio, May 2020

Adjuvant dabrafenib and trametinib provided long-term benefit for patients with resected stage III BRAF V600-mutant melanoma, according to an analysis of the COMBI-AD trial presented during the ASCO20 Virtual Scientific Program.

More than half of patients assigned the combination remained recurrence free at 5 years.

“The 5-year data are simply excellent,” Axel Hauschild, MD, PhD, professor of dermatology at University Hospital Schleswig-Holstein Campus Kiel in Germany, told Healio. “When the first data were released 3 years ago, I was surprised by the benefit. Now that we have longstanding good results, I’m not surprised because I was expecting the curves to flatten. Even though it met my expectation, to have 50% of patients with high-risk melanoma still without relapse at 5 years is a very good result.”